Teflaro's Patent and Exclusivity Timeline
Teflaro (ceftaroline fosamil), made by Allergan (now AbbVie), treats bacterial infections like skin and pneumonia. Its key U.S. patents expire in 2031, blocking generic entry until then.[1] Pediatric exclusivity adds six months, pushing full protection to mid-2032.[1][2]
When Will Generics Launch?
No generics are approved yet. The main composition patent (US 7,919,111) expires January 26, 2031. Without challenges, generics can't enter before that. FDA Orange Book lists no ANDAs filed or tentative approvals as of now.[2]
Are There Patent Challenges?
Two Paragraph IV challenges exist from generics firms:
- Sandoz: Filed ANDA in 2022; Allergan sued, case ongoing in NJ district court (no settlement).
- Lupin: Filed ANDA targeting same patents; litigation active.[1]
If challengers win, generics could launch post-30-month FDA stay (around 2025 for Sandoz). Most challenges settle earlier, but no deals here yet.[1]
Exclusivity Details
- New chemical entity exclusivity ended 2016.
- No remaining regulatory barriers beyond patents.[2]
Check DrugPatentWatch.com for real-time updates on lawsuits and expirations.[1]
How Does Teflaro Compare to Similar Antibiotics?
Unlike cephalosporins with earlier generics (e.g., ceftriaxone generics since 2007), Teflaro's unique MRSA coverage and patents delay competition. Alternatives like vancomycin generics are cheaper now (~$10/day vs. Teflaro's $200+/dose).[3]
Patient and Cost Impact
Generics could cut costs 80-90%, typical for antibiotics. Current shortages or high prices drive demand—watch for first filer 180-day exclusivity post-approval.[1][2]
Sources:
[1]: DrugPatentWatch.com - Teflaro Patents
[2]: FDA Orange Book - Teflaro
[3]: Drugs.com - Ceftaroline Pricing